Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
12/4/2006
 
First Published:
7/1/2001
1.
Phase III Randomized Study of 3 Regimens For the Prevention of Delayed Nausea After Chemotherapy in Patients With Chemotherapy-Naive Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 and over
NCI
URCC-U3901
NCI-P01-0180, NCT00020657
Last Modified:
5/31/2007
 
First Published:
8/1/1999
2.
Phase II Randomized Study of Acupressure and Acustimulation Wrist Bands for the Prevention of Chemotherapy Induced Nausea and Vomiting
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Closed
18 and over
Other
URCC-U3997
NCI-V99-1528, NCT00003817
Last Modified:
1/1/1992
3.
Antiemetic Retreatment Protocol with Single-Dose Intravenous MDL 73,147EF in Patients Receiving High-Dose (at Least 80 mg/sqm) Cisplatin (Summary Last Modified 01/92)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Closed
18 to 90
MSKCC-90151
NCI-V91-0013
Last Modified:
1/1/1992
4.
A Dose Escalation Tolerance Study of Intravenous MDL 73,147EF in Patients Receiving Chemotherapy Regimens Containing High-Dose (at least 100 mg/sqm) Cisplatin (Summary Last Modified 01/92)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Supportive care
Closed
18 and over
MSKCC-90150
NCI-V91-0012
Last Modified:
10/1/1995
5.
Randomized Comparative Study of 1 vs 2 Doses of Oral Dolasetron Mesylate/Dexamethasone as Antiemesis Prophylaxis in Patients Receiving Cisplatin (Summary Last Modified 10/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Supportive care
Completed
18 and over
MSKCC-95038
NCI-V95-0708
Last Modified:
6/1/1993
6.
Randomized, Double-Blind, Comparative Study of the Antiemetic Effectiveness of Single Dose IV Dolasetron Mesylate vs IV Ondansetron in Patients Receiving First-Line CDDP Chemotherapy (Summary Last Modified 06/93)
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Supportive care
Completed
18 and over
MSKCC-92141
NCI-V92-0193
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute